Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing
Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing
复制标题
DOI：
10.1007/s00259-016-3419-0
复制
发表时间：
2016-08-01
影响因子：
9.1
通讯作者：
Haberkorn, Uwe
中科院分区：
文献类型：
--
作者：
Afshar-Oromieh, Ali;Hetzheim, Henrik;Haberkorn, Uwe
目的针对前列腺特异性膜抗原(PSMA)的Ga-68-PSMA-11(“HBED-CC”)配体的临床应用被认为是前列腺癌(Pca)诊断的重要进展。在这项研究中，我们提供了注射后最佳PET成像时间的人体剂量学和数据。方法对4例复发的PCa患者进行Ga-68-PSMA-11PET/CT检查。分别于注射152-198MBq Ga-68-PSMA-11后5min、1h、2h、3h、4h和5h行全身PET/CT低剂量扫描。以中到高摄取的器官作为来源器官；在所有测量的时间点测定它们的总活性。为每个来源器官以及其余器官绘制了时间-活动曲线。使用Olinda-exm软件对Ga-68-PSMA-11 PET的辐射照射进行了鉴定。结果肾、肝、大肠上部和膀胱的示踪剂摄取率最高。平均器官剂量：肾脏0.262+/-0.098 mGyMBq，肝脏0.031+/-0.004 mGyMBq，大肠上段0.054+/-0.041 mGyMBq，膀胱0.13+-0.059 mGyMBq。计算的平均有效剂量为0.023+/-0.004 mSv/mBq(=0.085+/-0.015 rem/mci)。大多数肿瘤病灶(n=16)在P.I后3h可见，而在其他时间点均未定性(1h可见10/16)。结论Ga-68PSMA-11PET的平均有效剂量为0.023 mSv/MBq。在该患者队列中，注射后3h延迟是Ga-68-PSMA-11PET/CT的最佳时机。
Purpose The clinical introduction of Ga-68-PSMA-11 ("HBED-CC") ligand targeting the prostate-specific membrane antigen (PSMA) has been regarded as a significant step forward in the diagnosis of prostate cancer (PCa). In this study, we provide human dosimetry and data on optimal timing of PET imaging after injection.Methods Four patients with recurrent PCa were referred for Ga-68-PSMA-11 PET/CT. Whole-body PET/CTlow-dose scans were conducted at 5 min, and 1, 2, 3, 4 and 5 h after injection of 152-198MBq Ga-68-PSMA-11. Organs of moderate to high uptake were used as source organs; their total activity was determined at all measured time points. Time-activity curves were created for each source organ as well as for the remainder. The radiation exposure of a Ga-68-PSMA-11 PET was identified using the OLINDA-EXM software. In addition, tracer uptake was measured in 16 sites of metastases.Results The highest tracer uptake was observed in the kidneys, liver, upper large intestine, and the urinary bladder. Mean organ doses were: kidneys 0.262 +/- 0.098 mGy/MBq, liver 0.031 +/- 0.004 mGy/MBq, upper large intestine 0.054 +/- 0.041 mGy/MBq, urinary bladder 0.13 +/- 0.059 mGy/MBq. The calculated mean effective dose was 0.023 +/- 0.004 mSv/MBq (=0.085 +/- 0.015 rem/mCi). Most tumor lesions (n=16) were visible at 3 h p.i., while at all other time points many were not qualitatively present (10/16 visible at 1 h p.i.).Conclusions The mean effective dose of a Ga-68-PSMA-11 PET is 0.023 mSv/MBq. A 3-h delay after injection was optimal timing for Ga-68-PSMA-11 PET/CT in this patient cohort.